June 3, 2010 |
The Securities and Exchange Commission on Wednesday accused a former executive of San Diego-based biotech company Sequenom Inc. of lying to analysts about the accuracy of the company's prenatal screening test for Down syndrome. In a complaint filed in federal court in San Diego, the SEC alleged that Elizabeth A. Dragon, the company's former vice president of research and development, told analysts in 2008 and 2009 that the company's screening test could predict with nearly 100% accuracy whether a fetus would be born with Down syndrome.
February 1, 2000 |
San Diego-based biotech company Sequenom Inc. (SQNM) priced 5.25 million shares Monday at $26, above the expected range of $23 to $25, raising $136.5 million. The shares will begin trading today on Nasdaq. Sequenom, whose products to analyze genes are used in clinical trials and to develop drugs, sold 250,000 more shares than expected.
May 21, 2002 |
The annual meeting of the nation's cancer specialists, one of the largest and most closely watched medical gatherings of the year, often gives biotechnology stocks a fillip. Not this year. More bad news from ImClone Systems Inc., whose drug Erbitux failed in a mid-stage trial to halt or reverse the course of head and neck cancer, sent its shares tumbling $2.29, or 17%, to $11.12 on Monday.
May 30, 2001 |
San Diego-based Sequenom Inc. said Tuesday it will buy Britain's Gemini Genomics for $228 million in stock, part of a wave of consolidation in the emerging genomics industry. Sequenom said the tie-up would combine its genotyping technology platform with Gemini's expertise in population genetics, expanding their potential for disease-gene discovery.
February 9, 2000 |
The new biotech rush is on. Is it a prescription for disaster? With biotechnology stocks sizzling, start-ups are scrambling to get in on the action. According to Prudential Securities analyst Caroline Copithorne, 11 biotechs have filed already this year to make initial public offerings. That compares with 11 biotech companies for the entire 1999 calendar year. Genomics stocks have led the biotech sector's charge. Affymetrix Inc.
February 26, 2014 |
It's billed as a faster, safer and more accurate way of screening expectant mothers for fetal abnormalities like Down syndrome, and proponents say it has already become the standard for prenatal care. But as a handful of California companies market their DNA-testing services to a growing number of pregnant women, some experts complain that the tests have not been proven effective in the kind of rigorous clinical trials that are required of new drugs. Now, a study published Wednesday by the prestigious New England Journal of Medicine has verified that one of the tests can identify likely cases of Down syndrome and other genetic disorders caused by extra chromosomes in low-risk women with greater reliability than traditional noninvasive screening methods.